Elevation of early plasma biomarkers in patients with clinical risk factors predicts the increased nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: Biomarkers for nonrelapse mortality. Transplant Cell Ther. 2021.
Graft-versus-host disease prophylaxis using low-dose antithymocyte globulin in peripheral blood stem cell transplantation - A matched-pair analysis. Transplant Cell Ther. 2021.
Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2020.
Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia After an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of . Biol Blood Marrow Transplant. 2020.
Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. Biol Blood Marrow Transplant. 2020.
Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation: Allo-HSCT for patient. Biol Blood Marrow Transplant. 2020.
Mixed chimerism and secondary graft failure in allogeneic hematopoietic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2019.
Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. Leuk Res. 2018;75:50-57.
Comparison of HLA allele mismatch and antigen mismatch in unrelated bone marrow transplantation in patients with leukemia. Biol Blood Marrow Transplant. 2018.